Medical insurance-qualified stores and industry consolidation support recovery, but Goldman Sachs maintains a Neutral rating on LBX Pharmacy

Overview

This report is Goldman Sachs' meeting notes on LBX Pharmacy published after the 2026 China Healthcare Corporate Day. Management focused on the stabilization of the retail pharmacy industry after the downturn, the traffic advantage brought by stores qualified for outpatient medical insurance pooling, as well as 2026 operating guidance and medium-term expansion outlook. The report also reiterates Goldman Sachs' Neutral rating on LBX Pharmacy.

Core views

Goldman Sachs recognizes improvements in LBX Pharmacy in terms of industry supply-side consolidation, lower-tier city positioning, medical insurance-qualified stores, and recovery in mature-store same-store sales, but believes the company remains relatively weaker than major peers in financial flexibility and expansion capability. Industry consolidation and policy advancement are favorable to leaders, but companies with stronger balance sheets and M&A integration capabilities may find it easier to gain share.

Analysis framework

The report assesses the company based on management meeting notes, changes in industry store count, company store mix, medical insurance qualification coverage, same-store sales trends, the 2026 profit target, and Goldman Sachs' valuation framework, while also comparing LBX Pharmacy relatively with healthcare and pharmacy chain companies under coverage.

Methodology notes

• Research MethodologyChina Healthcare Corporate Day management communication

  Meeting notes

  The report is based on remarks made by Vice President and Board Secretary Shini Feng during the meeting, extracting key points on industry trends, operating recovery, store expansion, and profit targets.

• Valuation Methodology5-year exit P/E valuation

  12-month target price

  Goldman Sachs gives a 12-month target price of Rmb16 based on a 5-year exit P/E valuation method, using a WACC of 8.5% and an exit P/E of 18.2x.

• Equity Comparison FrameworkGoldman Sachs factor profile

  Growth, financial returns, valuation multiples, and composite percentile

  The Goldman Sachs factor profile compares the stock with the market and industry peers across growth, financial returns, valuation multiples, and composite indicators to provide relative investment context.

• M&A Assessment FrameworkM&A ranking

  Probability of being acquired score

  Goldman Sachs uses an M&A framework to assess the probability of the company becoming an acquisition target; rank 1 indicates high probability, rank 2 indicates medium probability, and rank 3 indicates low probability.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• LBX Pharmacy (603883.SS)

  Core covered target

  Strengths

  One of the industry leaders, covering 18 provinces in China; high proportion of stores in lower-tier cities; the proportion of stores qualified for outpatient medical insurance pooling is significantly higher than the industry; mature-store same-store sales have recovered from the 2025 low.

  Weaknesses

  Goldman Sachs believes its cash position is relatively tight, its historical expansion has relied more on franchising than acquisitions, and its financial flexibility and integration capability are relatively weaker than major peers.

  Comparison

  Against a backdrop of accelerating industry consolidation, pharmacy chain peers with stronger balance sheets and stronger M&A and integration capabilities may find it easier to gain market share.

  Risks

  Online competition exceeding expectations, policy advancement slower than expected, industry consolidation weaker than expected, M&A execution below expectations, or insufficient contribution from diversified businesses.

Key data

• Report date2026-06-29The cover page date of the report is 29 June 2026.
• Company and tickerLBX Pharmacy / 603883.SSThe subject is LBX Pharmacy, a Chinese retail pharmacy chain company.
• Goldman Sachs ratingNeutralGoldman Sachs maintains a Neutral rating.
• 12-month target priceRmb16Based on a 5-year exit P/E valuation, with a WACC of 8.5% and an exit P/E of 18.2x.
• Disclosed priceRmb10.99LBX Pharmacy's price is listed as Rmb10.99 in the company-specific disclosure.
• 2026 profit growth target21%Management maintains its 2026 profit growth target and has not disclosed formal revenue growth guidance.
• Mature-store same-store sales trendAbout -1% in 2025; about +2% in 1Q26; nearly +5% in 2Q26The improvement was mainly driven by higher traffic, while average ticket also improved moderately.
• 2026 new store plan2,100 storesIncluding about 1,200 franchise stores, 500 acquired stores, and 300 to 400 self-established stores.
• Lower-tier city footprint78% of stores are located in Tier-3 to Tier-5 citiesManagement believes competition is milder, costs are lower, margins are higher, and the impact from online O2O is weaker in these regions.
• Coverage of outpatient medical insurance pooling qualificationAbout 35% of directly operated storesThe industry-wide ratio is below 10%, and such stores deliver stronger traffic and same-store growth.
• Same-store growth advantage of medical insurance-qualified storesUp to about 15 percentage points in some periods; about 5 percentage points in 2025Management said there is a clear difference in same-store growth between medical insurance-qualified stores and non-qualified stores.
• Change in industry store countFrom about 700,000 to about 680,000The number of pharmacies nationwide declined in 2025, with small and independent stores being the main closures.
• Earnings forecastApproximately 15% earnings CAGR in 2023-2028EGoldman Sachs expects the company's earnings to maintain stable growth, but upside is constrained by its relative expansion capability.
• Cost structureAbout 80% of costs are fixed costsThe pharmacy industry has high operating leverage, and improved sales at mature stores may drive profit growth faster than revenue growth.

Impact & implications

For investors, the positive implication of this report is that the retail pharmacy industry may have passed its 2025 trough, with supply-side consolidation, medical insurance-qualified stores, and recovery in mature-store traffic potentially supporting profit improvement at LBX Pharmacy; limiting factors are the company's cash position, M&A integration capability, and a historical expansion model more reliant on franchising, meaning its ability to capture share relative to stronger peers still needs to be proven.

Risks

• Impact from online competition is stronger than expected.
• Policy implementation is slower than expected, or industry consolidation is weaker than expected.
• M&A execution and integration outcomes fall short of expectations, limiting the quality of store expansion.
• The company's cash position and financial flexibility are relatively weak, which may constrain expansion.
• If the franchise expansion model is not well managed, it may affect growth quality and earnings delivery.

What to watch

• Whether same-store sales can maintain around 5% growth after 2Q26.
• Whether the share of stores qualified for outpatient medical insurance pooling can continue to rise, and whether the gap in traffic and same-store growth versus non-qualified stores persists.
• The execution quality of the 2026 plan to add 2,100 stores, especially the 500 acquired stores.
• Whether the company's operating cash flow and financial position continue to improve.
• Updates to non-pharmaceutical sales policies and their impact on revenue mix and margins.
• Whether franchise expansion and low-valuation acquisitions can become more important growth drivers starting from 2027.